Sound Biologics
- Biotech or pharma, therapeutic R&D
We’re building new technologies and platforms to produce the next generation of therapeutic antibodies that are capable of targeting multiple molecules and pathways. We are seeking partners for molecules at different stages of development.
PSB205/QL1706 is the next generation dual targeting immune checkpoint inhibitor with better efficacy than PD1 monotherapy and improved safety profile than first generation PD1/CTLA-4 combination therapy. PSB205/QL1706 has been approved for the treatment of metastatic cervical cancer in China. PSB205 is currently being tested in multiple clinical trials, including five phase 3 trials, for different types of solid tumor.
PSB114/QLP2117, an ADCC enhanced CCR8 antibody that targets Tregs in solid tumor, is currently in phase 1b study in combination with ICI in China.
PSB219 is a bifunction product that targets both TSLP and IL33 for the treatment of asthma and COPD.
PSB128 (anti-amyloid-β) and PSB229 (anti-amyloid-β/TfR1) are at preclinical stage.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}